Drug Profile
Lovastatin modified release - Cedars-Sinai Medical Centre
Alternative Names: SYN-010Latest Information Update: 08 Oct 2021
Price :
$50
*
At a glance
- Originator Cedars-Sinai Medical Center
- Developer Synthetic Biologics
- Class Anti-inflammatories; Antihyperlipidaemics; Irritable bowel syndrome therapies; Naphthalenes
- Mechanism of Action HMG-CoA reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Irritable bowel syndrome
Most Recent Events
- 08 Oct 2021 Discontinued - Phase-II for Irritable bowel syndrome in USA (PO) (Synthetic Biologics pipeline, October 2021)
- 10 Nov 2020 Lovastatin modified release is no longer licensed to Synthetic Biologics worldwide
- 02 Oct 2020 Synthetic Biologics and Cedars-Sinai Medical Center terminated a phase IIb trial for Irritable bowel syndrome in USA after interim analysis (PO) (NCT03763175)